An open label extension study of etanercept biosimilar (YLB113) to assess long-term safety of YLB113 administration in subjects with rheumatoid arthritis
Latest Information Update: 24 Jun 2021
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 24 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism